Open Access Research article

In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis

Rogier AM Quax1*, Jan W Koper1, Pascal HP de Jong2, Ramona van Heerebeek1, Angelique E Weel3, Anne M Huisman4, Derkjen van Zeben4, Frank H de Jong1, Steven WJ Lamberts1, Johanna MW Hazes2 and Richard A Feelders1

Author Affiliations

1 Department of Internal Medicine, Erasmus MC, University Medical Center, 's-Gravendijkwal 230, Rotterdam, 3015 CE, The Netherlands

2 Department of Rheumatology, Erasmus MC, University Medical Center, 's-Gravendijkwal 230, Rotterdam, 3015 CE, The Netherlands

3 Department of Rheumatology, Maasstad Hospital, Maasstadweg 21, Rotterdam, 3079DZ, The Netherlands

4 Department of Rheumatology, Sint Franciscus Gasthuis, Kleiweg 500, Rotterdam, 3045PM, The Netherlands

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14:R195  doi:10.1186/ar4029

Published: 24 August 2012

Additional files

Additional file 1:

Table S1. Primer and probe sequences for GILZ, IL-2, and HPRT. This table gives the sequences of the primers and probes used in the bioassay to measure messenger RNA levels of GILZ, IL-2, and HPRT.

Format: DOCX Size: 12KB Download file

Open Data

Additional file 2:

Figure S2. Bivariate correlations between in vitro parameters of glucocorticoid sensitivity. This figure displays how different in vitro parameters of GC sensitivity, as measured in the bioassay and GC-binding assay, correlate to each other.

Format: DOC Size: 258KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data

Additional file 3:

Table S3. DAS and individual measures of the DAS in tREACH and FLARE patients. This table provides detailed information on DAS and individual measures of the DAS in the different subsets of studied patients, both at baseline and after 2 weeks of GC treatment.

Format: DOCX Size: 15KB Download file

Open Data